Market responds to aged care crisis & royal commission

Published 27-SEP-2018 10:35 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Julia Gillard had her Royal Commission into Institutional Responses to Child Sexual Abuse. Malcolm Turnbull had his Royal Commission into the Banking Sector. And mere weeks into his tenure as Prime Minister, Scott Morrison has announced his own Royal Commission — this time aimed at Australia's aged care sector.

It is a sector that’s had its fair share of bad PR in recent times. A year ago the topic received extra attention through the closure of the disgraced government-run Oakden nursing home in Adelaide.

After an investigation, SA’s chief psychiatrist uncovered abuse and neglect dating back 10 years. A ‘toxic culture of cover up’ was to blame for these issues going on for such a long time.

Considering the details that have emerged through the country’s two preceding royal commissions, we’ve come to be familiar with phrases like ‘toxic culture of cover up’ — it’s almost hard to feel truly shocked anymore.

‘ScoMo’ clearly believes there’s evidence of trends towards non-compliance and repeated failure to blow the whistle on horrible practices and mistreatment.

His announcement of the royal commission on Sunday was followed by a damning episode of the ABC’s Four Corners the following night.

And it seems the market was quick to respond, with three of Australia’s main listed aged care providers all taking a swift hit. Japara Healthcare Ltd (ASX:JHC), which closed last week at $1.67, opened on Monday at $1.40 — a drop of ~14%. While it recovered slightly on Tuesday, JHC’s stock price hit a low of $1.31 on Thursday, to end the week at around $1.38.

Having closed last week at $2.95, Estia Health Ltd (ASX:EHE) opened at $2.58 on Monday, and is currently sitting around $2.41 — now down ~18% since last Friday.

Then there’s Regis Healthcare Ltd (ASX:REG) which is down ~18% for the week, having opened 15.9% lower on Monday morning (from $3.61 on Friday) following Morrison’s announcement of the royal commission. REG are now at ~$2.96, and could well stay down for some time yet as stories of neglect from the company have already begun to surface.

We could be seeing a lot more downside where that came from.
Unfortunately for the out-of-favour sector, it’s not just shareholders looking to abandon ship. Macquarie analysts took 25% off the target prices of all three providers above — EHE, REG and JHC.

Those invested in the sector have good reason to be feeling uncomfortable about this week’s news.

According to Macquarie analysts, some of the earning risks now facing these players include falling occupancy rates (due to the likelihood of negative media coverage from a royal commission); and increased spending on compliance, marketing, PR and legal efforts as providers shift into damage control, or look to cover themselves as much as possible.

Knowing what we already know about the problems in the sector, it’s hard to predict how devastating the findings will be. Four Corners crowdsourced its two-part investigation and received a record-breaking 4000 responses from viewers, all eager to tell their stories.

Safe to say we can expect some tough times ahead for this sector.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.

tags

POLITICS


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X